Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence

This publication has 22 references indexed in Scilit:

• New developments in the management of head and neck cancer – impact of pembrolizumab
  Therapeutics and Clinical Risk Management, 2018
• Locoregionally recurrent head and neck squamous cell carcinoma: incidence, survival, prognostic factors, and treatment outcomes
  Oncotarget, 2017
• Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
  New England Journal of Medicine, 2016
• Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma
  Journal of Clinical Oncology, 2014
• Survival Patterns in Squamous Cell Carcinoma of the Head and Neck: Pain as an Independent Prognostic Factor for Survival
  The Journal of Pain, 2014
• Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials
  Annals of Oncology, 2014
• Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial
  Annals of Oncology, 2014
• Decision making in the management of recurrent head and neck cancer
  Head & Neck, 2013
• New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
  European Journal of Cancer, 2009
• Simple Predictors of Survival in Head and Neck Squamous Cell Carcinoma
  JAMA Otolaryngology–Head & Neck Surgery, 2002